Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$13.0B
77M shares
52-week range
$66.57 – $203.91
77% from low
Exchange
NASDAQ
CS
P/S (TTM)
1.6
EV / FCF (TTM)
11.8
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
www.iconplc.comNo one on the platform currently holds ICLR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 178,924 | $31.3M |
No one on the platform has traded ICLR yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.6% | 6.1% | 15.2% | — | — | — |
| Rev. Growth % | -0.4% | 24.2% | ||||
| Profit Margin % | 2.8% | 5.8% | 9.8% | |||
| Free Cash Flow Margin % | 10.4% | 11.1% | 11.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.8% on the P/E track.
At today's price, your expected annual return is +10.2% on the P/E track.
At today's price, your expected annual return is +14.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.1B | +1.2% | $10.60 | $10.52–$10.74 | 16.3× | 10 |
| 2027 | $8.4B | +3.7% | $11.94 | $10.77–$13.15 | 14.4× | 10 |
| 2028 | $8.9B | +5.6% | $13.56 | $10.55–$16.30 | 12.7× | 7 |
| 2029 | $9.6B | +8.2% | $15.83 | $15.48–$16.28 | 10.9× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $2.55 | $2.56 | +0.4% |
| 2026-06-23 | $2.46 | $2.50 | +1.6% |
| 2026-05-27 | $3.13 | $2.52 | -19.5% |
| 2025-10-22 | $3.28 | $3.31 | +0.9% |
| 2025-07-23 | $3.19 | $3.26 | +2.2% |
| 2025-04-30 | $3.11 | $3.19 | +2.6% |
| 2025-02-19 | $3.41 | $3.43 | +0.6% |
| 2024-10-23 | $3.84 |
| $3.35 |
| -12.8% |
| $23.8B |
| — |
| MEDPMedpace Holdings, Inc. | $620.99 | +4.30% | $17.3B | — |
| NBIXNeurocrine Biosciences, Inc. | $150.63 | -4.19% | $15.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 2.68 EPS for $ICLR Q3 [Reporting 10/28 AMC] http://www.estimize.com/intro/iclr?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
$ICLR looks ready to bounce off the 50 day average (correction to my earlier post)
View on StockTwits ↗$ICLR nice uptrend dip bouncing off the 50 day average
View on StockTwits ↗Wall St is expecting 2.71 EPS for $ICLR Q3 [Reporting 10/28 AMC] http://www.estimize.com/intro/iclr?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
$ICLR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.94 down -63.42% YoY • Reported revenue of $2.06B up 1.20% YoY • ICON plc is reaffirming its 2026 full-year financial guidance, with revenue expected in the range of $7,850 million to $8,150 million and adjusted diluted earnings per share between $10.00 and $11.00.
View on StockTwits ↗
$ICLR (+5.2% pre) ICON and Anthropic Plan AI to Spot Trial Enrollment Risks https://ooc.bz/l/108816
View on StockTwits ↗
Wall St is expecting 2.56 EPS for $ICLR Q2 [Reporting 07/29 AMC] http://www.estimize.com/intro/iclr?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
$ICLR Current Stock Price: $168.30 Contracts to trade: $170.0 ICLR Jul 17 2026 Call Entry: $6.50 Exit: $12.09 ROI: 86% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗
@cynicaloptimist @BustaCapital @Jblack500 @IsabellaDC @WAJeff @No_Face_character $ICLR $TWST ing $NTRA - tagging on
View on StockTwits ↗RECAP 6/25 +Pos Comments: $ICLR + RBC Capital RECAP 6/25 -Neg Comments: $VELO - Morpheus $SILA - Truist Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗
@No_Face_character @Jblack500 @WAJeff @cynicaloptimist @IsabellaDC @BustaCapital $ICLR $WGS $NTRA ...
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.